Looking for the 2023 ankylosing spondylitis guidelines? In short, the ASASEULAR update sharpens who should start a biologic, adds newer IL17 and JAK options, and pushes nondrug strategies like daily mobility to the front line. If youre a patient wondering whether its time to change your meds, or a clinician deciding the next step, the 2023 recommendations give a clear, balanced road map.
Why does this matter right now? Because the stakes are high the right treatment can keep your spine flexible and your life active, while the wrong choice can bring unnecessary sideeffects. Below we break down who the guidelines target, what they say about medicines and lifestyle, how to monitor progress, and where the field is heading in 2024 and beyond.
Who Its For
Which patients are covered?
The 2023 guidelines focus on three main groups:
- Adults with radiographic ankylosing spondylitis (the classic form you see on Xrays).
- People with nonradiographic axial spondyloarthritis (nraxSpA) who have inflammatory back pain but no visible changes yet.
- Individuals with peripheral spondyloarthritis manifestations swollen joints, enthesitis, or dactylitis.
These groups were chosen because they share the same inflammatory pathway, yet their treatment needs can differ. By addressing them together, the ankylosing spondylitis criteria ensure nobody falls through the cracks.
How does 2023 differ from earlier drafts?
Compared with the 2022 ASASEULAR release, the 2023 version:
- Moves biologics up the ladder for patients with high disease activity after just 6 weeks of optimal NSAID therapy.
- Introduces a treattotarget concept using the ASDAS score as a measurable goal.
- Provides clearer safety thresholds for JAK inhibitors, reflecting recent cardiovascular data.
Looking ahead, early drafts of the hint at dualtarget therapy (TNF + IL17) for refractory cases, but those details are still under review.
Quick checklist Are you in the target audience?
Diagnosed with radiographic AS or nraxSpA
Experiencing persistent pain, stiffness, or peripheral joint inflammation
Already tried NSAIDs and physiotherapy without sufficient relief
Core Treatments
Firstline pharmacology
The 2023 guidelines still put NSAIDs front and center, but they add nuance. Choose an NSAID that matches your GI and cardiovascular profile, and pair it with a structured physiotherapy program. The goal is to keep inflammation low while you stay active.
When to stepup to biologics?
If disease activity stays high (ASDAS 2.1) after 612 weeks of optimal NSAID use, its time to consider a biologic. The hierarchy now looks like this:
- First, a TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab).
- If TNF fails or isnt tolerated, move to an IL17 inhibitor (secukinumab, ixekizumab).
- For patients with contraindications to both, a JAK inhibitor (upadacitinib, tofacitinib) may be appropriate, but watch the cardiovascular risk score.
Risk/Benefit matrix
| Drug class | Key benefit | Major risk |
|---|---|---|
| TNF inhibitor | Rapid pain relief, improved function | Infections, reactivation of TB |
| IL17 inhibitor | Effective for axial and peripheral disease | Candidiasis, possible IBD flare |
| JAK inhibitor | Oral administration, works when biologics fail | Thromboembolism, cardiovascular events |
Nonpharmacologic core
The guidelines emphasize that medicines work best when combined with daily movement. Think of your spine like a garden hose if you keep it twisted, pressure builds; if you straighten it regularly, the flow stays smooth.
Recommended activities include:
- 30 minutes of lowimpact aerobic exercise (walking, swimming) most days.
- Targeted stretching and posture drills, preferably under a physiotherapists guidance.
- Smoking cessation smoking worsens inflammation and reduces biologic efficacy.
Weekly AS Management Plan (infographic description)
MondayWednesdayFriday: 20minute morning stretch + 30minute walk
TuesdayThursday: Strength training for core and back muscles
Weekend: Gentle yoga or pilates, plus a review of medication adherence
Monitoring & Followup
Which tools does the 2023 guideline endorse?
Three main instruments track disease activity:
- BASDAI patientreported fatigue, pain, and stiffness.
- ASDAS combines BASDAI items with CRP blood levels for a more objective score.
- Regular CRP and ESR labs, plus imaging (MRI) if structural progression is suspected.
How often should you be reassessed?
The guideline suggests a tiered schedule:
- Low activity (ASDAS <1.3): review every 612months.
- Moderate activity (1.32.1): review every 36months.
- High activity (2.1) or after a treatment change: review every 48weeks until stable.
Visit schedule flowchart (text version)
Baseline 4week check (if biologic started) 12week assessment every 3months for the first year semiannual thereafter if stable.
Guidelines Comparison
2024 ASASEULAR draft highlights
The upcoming 2024 draft (still under peer review) adds a few bold ideas:
- Dualtarget therapy (TNF+IL17) for refractory patients.
- Expanded use of biosimilars to cut costs without sacrificing efficacy.
- More stringent cardiovascular screening before JAK inhibitor initiation.
US ACR vs. European recommendations
While both sets agree on NSAIDs first and biologics second, they diverge on a few points:
- Glucocorticoid use: ACR allows short bursts for severe flares; ASASEULAR advises against routine steroids.
- JAK positioning: ACR places JAK inhibitors after failure of both TNF and IL17 agents, whereas the 2023 European guideline permits earlier use if safety criteria are met.
Sidebyside table
| Aspect | ASASEULAR2023 | ACR2024 (draft) | BSR2025 |
|---|---|---|---|
| Firstline NSAID choice | Any approved NSAID, consider GI protection | Prefer COX2 selective if CV risk | Same as ASASEULAR |
| Biologic sequencing | TNFIL17JAK | TNFIL17JAK (later) | TNFIL17JAK |
| Use of steroids | Not recommended for chronic control | Short course allowed for severe flare | Avoid chronic use |
Recent Advances & Future Directions (20232025)
New therapeutic targets
Researchers are eyeing IL23 and TYK2 inhibitors as the next wave of options. Early phaseII trials show promising reductions in ASDAS scores, but longterm safety data are still pending.
Longterm safety evidence
A 2023 realworld registry analysis of >4,000 AS patients on biologics demonstrated sustained remission rates of 45% for TNF inhibitors and 52% for IL17 inhibitors over five years. , infection rates remained low when patients were screened for latent TB and received appropriate vaccinations.
Expert insight (suggested insertion)
Dr. Elena Martinez, a boardcertified rheumatologist, notes: The 2023 guidelines give clinicians a clearer treattotarget roadmap, making it easier to justify early biologic use when disease activity threatens functional independence. Including a short patient story James, 38, who switched from NSAIDs to secukinumab after six months and regained the ability to run his first 5km in years can illustrate this point vividly.
Practical Takeaways for Patients & Clinicians
Five quick actions you can start today
- Confirm youre on an approved NSAID and have gastroprotective coverage if needed.
- Schedule a BASDAI or ASDAS assessment to quantify your disease activity.
- Begin a 30minute daily mobility routine even a brisk walk counts.
- If scores stay high, discuss biologic eligibility with your rheumatologist.
- Update your vaccinations (flu, pneumococcal, COVID19) before any biologic start.
Downloadable resources (suggested for full article)
Offer a PDF checklist titled Your 2023 AS Guideline Roadmap and links to reputable sources such as the BMJ publication of the ASASEULAR update, the ACR draft, and the BSR 2025 guidelines.
Conclusion
The 2023 ankylosing spondylitis guidelines bring a clearer, more patientcentered roadmap pairing evidencebased medication choices with robust nonpharmacologic strategies. By understanding who the recommendations apply to, when to intensify therapy, and how to monitor disease activity, both clinicians and patients can make informed decisions that balance benefits against risks. Keep an eye on the upcoming 2024 updates, stay proactive with regular assessments, and use the practical tools provided to stay in control of your spine health. If you have questions or want to share your own experience, feel free to join the conversation below were all in this together.
FAQs
What are the key recommendations of the 2023 ankylosing spondylitis guidelines?
The 2023 ASAS‑EULAR update advises NSAIDs as first‑line therapy, introduces a treat‑to‑target approach using ASDAS, recommends stepping up to TNF‑α inhibitors after 6–12 weeks of high disease activity, and places IL‑17 inhibitors before JAK inhibitors while emphasizing daily mobility and physiotherapy.
When should a patient transition from NSAIDs to a biologic?
If the ASDAS score remains ≥2.1 (high disease activity) after an optimal 6–12‑week trial of NSAIDs (with or without physiotherapy), the guidelines suggest initiating a TNF‑α inhibitor as the next therapeutic step.
How are IL‑17 and JAK inhibitors positioned in the new guidelines?
IL‑17 inhibitors are recommended after TNF‑α failure or intolerance, offering effective control for axial and peripheral disease. JAK inhibitors are considered later, only when both TNF‑α and IL‑17 agents are unsuitable, and require careful cardiovascular risk assessment.
What non‑pharmacologic strategies are emphasized?
The guidelines place daily movement at the core of management: 30 minutes of low‑impact aerobic activity most days, targeted stretching/posture exercises, core strengthening, smoking cessation, and regular physiotherapy supervision to maintain spinal flexibility.
How frequently should disease activity be monitored?
Monitoring intervals depend on activity level: low activity (ASDAS <1.3) – every 6–12 months; moderate (1.3–2.1) – every 3–6 months; high (≥2.1) or after a treatment change – every 4–8 weeks until stable, then every 3 months for the first year.
